Direct-to-consumer genetic testing has moved from a novelty into a mainstream consumer product, with millions of people having submitted a saliva sample for ancestry and health-related genetic reports. The clinical value of these reports varies enormously depending on the specific category of result, and understanding that variation is essential to interpreting a consumer genetic report responsibly rather than either dismissing or over-relying on it.
FDA-Authorized Health Reports Versus Unregulated Ancestry Features
A subset of direct-to-consumer health-related genetic reports have gone through FDA review and authorization — including reports on specific, well-characterized genetic variants like certain BRCA1/BRCA2 mutations associated with hereditary breast and ovarian cancer risk, and reports on carrier status for certain recessive genetic conditions. These FDA-authorized reports are held to a defined accuracy and clinical validity standard. Ancestry composition estimates and many "trait" reports (predicting characteristics like caffeine metabolism or muscle composition), by contrast, are not subject to the same regulatory scrutiny and vary in their underlying scientific rigor.
The BRCA Testing Limitation Most Users Do Not Realize
A commonly cited example of where consumer expectations can outpace what the test actually covers involves BRCA testing: the FDA-authorized consumer BRCA report tests only for a specific, limited set of well-characterized variants most common in people of Ashkenazi Jewish descent — not the full range of BRCA1/BRCA2 mutations that can cause hereditary cancer risk. A negative result on this limited consumer panel does not rule out a different, untested BRCA mutation, a distinction that has led to documented cases of patients incorrectly assuming a negative direct-to-consumer result meant they had no elevated hereditary cancer risk, when in fact they simply had not been tested for the specific mutation relevant to their family history.
Polygenic Risk Scores Remain an Evolving, Contested Area
Some consumer genetic platforms now offer polygenic risk scores — estimates of disease risk based on the combined small effects of many genetic variants across the genome — for conditions like type 2 diabetes, coronary artery disease, and certain cancers. While an active and genuinely promising area of ongoing research, polygenic risk score validity and clinical utility for individual decision-making remain considerably less established than single-gene test results for well-characterized conditions, and these scores have shown documented accuracy variation across different ancestral populations, since most underlying research cohorts have historically been drawn predominantly from European-ancestry populations.
Why Clinical Confirmation Testing Still Matters
Any clinically significant direct-to-consumer genetic finding — particularly one suggesting elevated hereditary cancer or disease risk — generally warrants confirmation through clinical-grade genetic testing ordered by a physician or genetic counselor, both because consumer test accuracy standards and quality control processes differ from clinical laboratory standards, and because a genetic counselor can properly interpret the finding in the context of personal and family history before any major medical decision is made based on the result.
Genetic Counseling Access Has Not Kept Pace With Testing Volume
The rapid growth in consumer genetic testing volume has outpaced the supply of trained genetic counselors available to help interpret results and guide follow-up decisions, particularly for the subset of consumers who receive an unexpected, clinically significant finding without having sought testing specifically for that purpose. This access gap has driven growth in telehealth-based genetic counseling services specifically to meet demand that in-person genetic counseling capacity alone cannot serve.
Conclusion
Direct-to-consumer genetic testing offers real value for FDA-authorized, well-characterized health reports, but consumers should understand the specific scope and limitations of any given result — particularly for conditions like hereditary cancer risk where a negative consumer result may not rule out a clinically significant mutation outside the tested panel. Any significant finding warrants clinical confirmation and genetic counseling before acting on it. Clinical genetics programs supporting this follow-up testing rely on accurate lab supplies for confirmatory diagnostic work.
